Tissue-targeted Immune Modulation

EUPRAXIA PHARMACEUTICALS is a clinical-stage biotechnology company
leveraging proprietary and innovative delivery technology with the
goal of providing
the right dose of drug in the
right place for the
right amount of time
in indications with a high unmet medical need

Our Technology

About Eupraxia Pharmaceuticals


Our Team

Eupraxia is proud of its experienced team of life science professionals.

Learn More


Our Lead Candidate

EP-104 is designed to address significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE).

Learn More


Our Pipeline

Our technology platform may be suitable for a wide range of indications and drugs that could be improved by locally targeted and extended release.

Learn More

View all news

Latest News